EBS vs. BCRX, DVAX, GERN, CLDX, MNKD, MYGN, NVAX, INVA, OPK, and RIGL
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Geron (GERN), Celldex Therapeutics (CLDX), MannKind (MNKD), Myriad Genetics (MYGN), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.
Emergent BioSolutions vs.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
BioCryst Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
Emergent BioSolutions has a net margin of -18.55% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Emergent BioSolutions' return on equity.
BioCryst Pharmaceuticals received 60 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.77% of users gave Emergent BioSolutions an outperform vote while only 66.67% of users gave BioCryst Pharmaceuticals an outperform vote.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
BioCryst Pharmaceuticals presently has a consensus target price of $15.50, suggesting a potential upside of 68.30%. Emergent BioSolutions has a consensus target price of $14.33, suggesting a potential upside of 85.16%. Given Emergent BioSolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals has higher earnings, but lower revenue than Emergent BioSolutions. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Emergent BioSolutions. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 3 mentions for Emergent BioSolutions. Emergent BioSolutions' average media sentiment score of 0.20 beat BioCryst Pharmaceuticals' score of 0.15 indicating that Emergent BioSolutions is being referred to more favorably in the news media.
Summary
BioCryst Pharmaceuticals beats Emergent BioSolutions on 10 of the 18 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
This page (NYSE:EBS) was last updated on 2/21/2025 by MarketBeat.com Staff
Free EBS Stock Alerts